Valence 로고
인기
로그인
Loading data for ADPT — first visit, this takes a few seconds.

관심목록에 추가

Adaptive Biotechnologies ...

NasdaqGS: ADPT · 실시간 가격 · USD
24.74
+0.28 (1.14%)
종가 기준: Aug 14, 2026, 8:00 PM
24.75
+0.04%
애프터마켓: 7:47 PM

Adaptive Biotechnologies Corporation (ADPT) Stock Price, Analysis & Data

1.14%

데이터 없음

매수호가17.86
시가총액3.94B
매출 (ttm)308.08M
순이익 (ttm)-63.85M
베타2.09
EPS (ttm)-0.4
P/E (ttm)n/a
선행 P/E-133.93
P/B (ttm)27.55
P/S (ttm)12.77
Earnings DateNov 4, 2026
매도호가24.75
거래량1,743,593
평균 거래량 (20일)2,931,406
시가24.27
전일 종가24.46
일중 범위24.00 - 24.95
52주 범위11.92 - 26.16
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

ADPT 소개

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining num...

[더 보기]
산업 Diagnostics & Research
섹터 Healthcare
IPO 일자 Jun 27, 2019
직원 수 624
상장 거래소 NasdaqGS
티커 ADPT
웹사이트 https://www.adaptivebiotech.com
전체 기업 정보

재무 실적

2025년 Adaptive Biotechnologies의 매출은 276.98M로, 전년 178.96M 대비 54.77% 증가했습니다. 순이익은 -59.5M로, -62.69% 감소했습니다.

재무제표

어닝 서프라이즈

Adaptive Biotechnologies가 Jul 29, 2026에 분기 실적을 발표했습니다:
  • 매출 n/a 예상치 하회 $0, 및 -100.00% 전년 대비 감소.
  • EPS -0.25 예상치 하회 -0.12, 및 -47.06% 전년 대비 감소.

    • 다음 실적 발표

    Adaptive Biotechnologies Corporation의 실적 발표 예정일은 Nov 4, 2026, 정규장 중입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    2주 전 · GuruFocus.com

    Adaptive Biotechnologies Corp (ADPT) (Q2 2026) Earnings Call Highlights: MRD Revenue Surges ...

    Adaptive Biotechnologies Corp (ADPT) reports a strong Q2 with MRD revenue up 49% (ex-milestones) and raises full-year guidance, while progressing the separation of its Immune Medicine business.

    news image

    2주 전 · Zacks

    Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

    While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key m...

    news image

    2주 전 · Zacks

    Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

    Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stoc...

    news image

    2주 전 · MarketBeat

    Adaptive Biotechnologies Q2 Earnings Call Highlights

    Adaptive Biotechnologies (NASDAQ:ADPT) reported second-quarter results marked by accelerating growth in its minimal residual disease, or MRD, business, improved margins and an increased full-year reve...

    news image

    3주 전 · Simply Wall St.

    Adaptive Biotechnologies (ADPT) After Loss Forecasts Improve Is The Rally Already Priced In

    Investors are watching Adaptive Biotechnologies (ADPT) after forecasts pointed to a reduced quarterly loss of $0.13 per share and 12.6% revenue growth for the June 2026 quarter, alongside its track re...

    2 페이지 중 1